Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis
- 5 January 2021
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 62 (6), 1432-1440
- https://doi.org/10.1080/10428194.2020.1864354
Abstract
We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (whole cohort) was 30% with a median overall survival of 4.7 months. First-line patients achieved better responses than r/r-patients (ORR: 38% vs. 21%) resulting in a median OS of 5.8 months vs. 3.9 months. NGS based mutation analysis was performed in 180 patients. 20 patients (11%) harbored a TP53 mutation. Response rates and survival did not differ significantly between TP53 mutated patients and wild-type patients. This analysis of a large cohort of AML patients provides response rates and OS data after decitabine treatment. Interestingly, outcome was not negatively influenced by a TP53 mutation.Keywords
This publication has 42 references indexed in Scilit:
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood, 2019
- Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantationAnnals of Hematology, 2017
- Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemiaBlood, 2017
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015
- Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutationsLaboratory Investigation, 2014
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcomeBlood, 2012
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009